Invitrogen™ c-Met Monoclonal Antibody (3D4)

Beschreibung

This antibody is specific for the cytoplasmic domain of the c-Met protein. On western blotting, this antibody recognizes a band at approximately 145 kDa. During development reactivity was confirmed with human HT-29 breast carcinoma lysates and c-Met cytoplasmic domain recombinant protein by both western blot, and with formalin-fixed, paraffin-embedded breast carcinoma tissues by immunohistochemistry. For immunohistochemistry with formalin-fixed, paraffin-embedded tissues, heat-induced epitope retrieval (HIER) with citrate buffer, pH 6.0, is required prior to staining. Recommended antibody incubation period is overnight at 4°C.

MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.